US FDA staff questions dosing of Lucentis eye drug

WASHINGTON (Reuters) - U.S. drug reviewers on Tuesday said Roche Holding AG's eye drug Lucentis (ranibizumab injection) appeared to help patients with diabetic macular edema (DME), but questioned whether two different doses of the drug were equally safe and effective.

Full Story →